Want to see HK:2561 full AI Analyst Report?
Top Page
VISEN Pharmaceuticals
(2561)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$18.50
▼(-45.07% Downside)
Action:Reiterated
Date:09/14/26
The score is held down primarily by weak financial performance—large ongoing losses and very heavy negative operating/free cash flow—despite a notable TTM revenue rebound and a balance sheet with moderate leverage. Technicals also remain soft with the share price below major moving averages and negative MACD, while valuation support is limited by negative earnings and no provided dividend yield.
Positive Factors
Sharp TTM revenue rebound
The sharp TTM revenue rebound indicates materially improved commercial traction and a stronger base for future operating leverage. If this growth is sustained, it could help VISEN spread its fixed cost structure over greater sales and progressively improve its earnings profile.
Negative Factors
Very large continuing net losses
The substantial TTM net loss shows that current revenue is far below the level needed to support the company's operating structure. Persistent losses can consume equity, reduce funding flexibility, and delay the point at which the business can become self-sustaining.
Read all positive and negative factors
Positive Factors
Negative Factors
Sharp TTM revenue rebound
The sharp TTM revenue rebound indicates materially improved commercial traction and a stronger base for future operating leverage. If this growth is sustained, it could help VISEN spread its fixed cost structure over greater sales and progressively improve its earnings profile.
Read all positive factors
VISEN Pharmaceuticals (2561) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.20B
Dividend YieldN/A
Average Volume (3M)22.20K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees82
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-2.20
Shares Outstanding113,926,865
10 Day Avg. Volume18,240
30 Day Avg. Volume22,200
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)4.01
Price to Sales (P/S)19001.90
P/FCF Ratio-6.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.12
Revenue Forecast (FY)HK$67.73M
VISEN Pharmaceuticals Business Overview & Revenue Model
Company Description
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-...
VISEN Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.40M | 160.73K | 2.78M | -1.67M | -2.30M |
| Gross Profit | 3.78M | 18.51K | 2.78M | -1.67M | -2.30M |
| EBITDA | -235.50M | -249.16M | -177.62M | -242.26M | -280.95M |
| Net Income | -239.50M | -246.86M | -182.24M | -249.57M | -288.97M |
Balance Sheet | |||||
| Total Assets | 887.16M | 977.72M | 293.82M | 443.80M | 741.27M |
| Cash, Cash Equivalents and Short-Term Investments | 505.81M | 632.92M | 203.59M | 347.78M | 626.46M |
| Total Debt | 176.71M | 177.06M | 2.36M | 3.65M | 6.00M |
| Total Liabilities | 215.91M | 215.34M | 52.55M | 52.92M | 88.67M |
| Stockholders Equity | 671.25M | 762.38M | 241.28M | 390.88M | 652.61M |
Cash Flow | |||||
| Free Cash Flow | -459.94M | -450.16M | -140.97M | -271.83M | -248.31M |
| Operating Cash Flow | -458.10M | -447.58M | -140.86M | -271.31M | -246.55M |
| Investing Cash Flow | -3.13M | 6.67M | -117.00K | -520.00K | -1.77M |
| Financing Cash Flow | 161.52M | 870.00M | -3.09M | -6.95M | -7.95M |
VISEN Pharmaceuticals Technical Analysis
Negative
33.68
Price Trends
19.72
Negative
21.19
Negative
26.69
Negative
Market Momentum
-0.16
Positive
45.30
Neutral
37.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2561, the sentiment is Negative. The current price of 33.68 is above the 20-day moving average (MA) of 19.69, above the 50-day MA of 19.72, and above the 200-day MA of 26.69, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 45.30 is Neutral, neither overbought nor oversold. The STOCH value of 37.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2561.
VISEN Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$198.42B | 26.75 | 18.26% | 1.25% | 24.97% | 43.23% | |
60 Neutral | HK$17.85B | 147.50 | 1.43% | ― | -8.55% | -96.20% | |
59 Neutral | HK$14.75B | 68.84 | 1.67% | 3.96% | 3.10% | -46.64% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | HK$11.89B | 331.92 | 0.82% | 1.31% | 38.42% | ― | |
52 Neutral | HK$2.38B | -20.12 | -10.61% | ― | 83.49% | -110.21% | |
43 Neutral | HK$2.20B | -7.51 | -33.42% | ― | ― | ― |
* General Sector Average
HK:2561
VISEN Pharmaceuticals
19.32
-26.16
-57.52%
HK:0013
HUTCHMED (China)
21.40
-5.52
-20.51%
HK:2552
Hua Medicine
2.40
-1.86
-43.66%
HK:9989
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
4.20
-1.49
-26.25%
HK:3692
Hansoh Pharmaceutical Group Company Limited
34.40
-0.84
-2.38%
HK:6185
CanSino Biologics, Inc. Class H
26.46
-27.09
-50.59%
VISEN Pharmaceuticals Corporate Events
VISEN Pharmaceuticals Posts Interim 2026 Results and Adjusts Board Committees
Aug 27, 2026
VISEN Pharmaceuticals has released its unaudited interim results for the six months ended June 30, 2026, with the figures reviewed by its audit committee and external auditor Ernst Young in line with Hong Kong listing requirements. The company wi...
VISEN Pharmaceuticals Details Board and Committee Structure
Aug 27, 2026
VISEN Pharmaceuticals has outlined the composition of its board of directors, detailing the mix of executive, non-executive and independent non-executive members and confirming FU Shan as chairman. The board’s configuration underscores a gov...
VISEN Pharmaceuticals Sets Board Meeting to Approve 2026 Interim Results
Aug 17, 2026
VISEN Pharmaceuticals has scheduled a board meeting for 27 August 2026 to review and approve the group’s interim results for the six months ended 30 June 2026. The meeting will also address other corporate matters, signaling routine financia...
VISEN Pharmaceuticals Grants Performance-Linked Share Awards to Key Staff
Jul 20, 2026
VISEN Pharmaceuticals has granted 514,068 share awards to 19 senior managers and employees under its existing share award scheme, with no purchase price payable by the grantees. The awards, tied to the company’s Hong Kong-listed shares, are ...
VISEN Pharmaceuticals Shareholders Approve All AGM Resolutions and Expand Board
Jun 26, 2026
VISEN Pharmaceuticals reported that all ordinary resolutions at its 26 June 2026 annual general meeting were duly passed by shareholders via poll voting, including approval of the 2025 audited financial statements and the re-election of key execut...
VISEN Pharmaceuticals Clarifies Board Structure and Committee Roles
Jun 26, 2026
VISEN Pharmaceuticals has published an updated list of its board of directors and detailed the roles and functions they hold within the company. The announcement confirms the composition of the board, including one executive director, multiple non...
VISEN Pharmaceuticals Adds New Director Appointments to AGM Agenda
Jun 17, 2026
VISEN Pharmaceuticals has issued a supplemental notice to its previously announced annual general meeting, confirming that the AGM will still take place in Shanghai on June 26, 2026, at 10:00 a.m. local time. The company is adding three new ordina...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.